| Aug 16 |
Alvotech (ALVO) Q2 2024 Earnings Call Transcript
|
| Aug 16 |
Alvotech 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 15 |
Alvotech GAAP EPS of -$0.61, revenue of $236M
|
| Aug 15 |
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
|
| Aug 15 |
Alvotech’s biosimilar to Regeneron’s Eylea under EU review
|
| Aug 15 |
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
|
| Jun 26 |
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
|
| Jun 11 |
Alvotech and Stada add to strategic alliance through denosumab partnership
|
| Jun 11 |
Alvotech and STADA add to strategic alliance through denosumab partnership
|
| Jun 7 |
Alvotech enters $965M refinancing agreement
|
